DM Dr. Martens plc Stock: price and management transactions · United Kingdom · RNS (LSE)Follow the Dr. Martens plc share price and the full directors' dealings record of the company, a publicly traded company based in United Kingdom. Shares are listed on the UK market, under the oversight of RNS (LSE). Operating in the Luxury & Fashion sector, Dr. Martens plc has published 128 reports. Market capitalisation: €847.1m. The latest transaction was disclosed on 16 August 2026 (Purchase). Among the most active insiders: Giles Wilson. The full history is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,787 of 28,551 companies
FCF yld 16%
Earn yld 2.8%
EV/EBITDA 9.7x
ROE 6.5%
Gross mgn 66%
Net mgn 3.1%
Debt/EBITDA 3.1x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 August 2026
All Executives128 Thresholds0 Prospectus0 Other0
Declarations 128 total
● PDMR (Chief Financial Officer) · Executives · 11 Aug 2026
358 shares @ £0.4189 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9720863-1 ● PDMR (Chief Executive Officer) · Executives · 11 Aug 2026
358 shares @ £0.4189 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9720863-0 ● PDMR (Chief Executive Officer) · Executives · 13 Jul 2026
404 shares @ £37.1334 0.21% mcap 2.4% of flow 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9672919-0 ● PDMR (Chief Financial Officer) · Executives · 13 Jul 2026
404 shares @ £37.1334 0.21% mcap 5.4% of flow 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9672919-1 ● PDMR (Chief Executive Officer) · Executives · 13 Jul 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:81f51376-e262-44fa-a229-43dd2eba7595-0 ● PDMR (Chief Financial Officer) · Executives · 13 Jul 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:81f51376-e262-44fa-a229-43dd2eba7595-1 ● PDMR (Chief Executive Officer) · Executives · 25 Jun 2026
118,516 shares @ £0.717 1.18% mcap 13.3% of flow London Stock Exchange (XLON)ISIN ISIN GB00BL6NGV24RNS:9639256-0 ● PDMR (Chief Financial Officer) · Executives · 25 Jun 2026
68,313 shares @ £0.717 0.68% mcap 17.5% of flow London Stock Exchange (XLON)ISIN ISIN GB00BL6NGV24RNS:9639256-1 ● PDMR (Chief Executive Officer) · Executives · 25 Jun 2026
118,516 shares @ £0.717 0.014% mcap 13.6% of flow London Stock Exchange (XLON)ISIN ISIN GB00BL6NGV24RNS:cb007bcf-1129-47fc-a1bf-bab8e4432846-0 ● PDMR (Chief Financial Officer) · Executives · 25 Jun 2026
68,313 shares @ £0.717 0.0082% mcap 18.5% of flow London Stock Exchange (XLON)ISIN ISIN GB00BL6NGV24RNS:cb007bcf-1129-47fc-a1bf-bab8e4432846-1 ● PDMR (Chief Executive Officer) · Executives · 11 Jun 2026
404 shares @ £37.1848 0.0025% mcap 3.3% of flow 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9620596-0 ● PDMR (Chief Financial Officer) · Executives · 11 Jun 2026
404 shares @ £37.1848 0.0025% mcap 9.0% of flow 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9620596-1 ● PDMR (Chief Executive Officer) · Executives · 11 Jun 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:edd7caa0-aaea-48b6-91bc-889e396db09b-0 ● PDMR (Chief Financial Officer) · Executives · 11 Jun 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:edd7caa0-aaea-48b6-91bc-889e396db09b-1 ● PDMR (Chief Executive Officer) · Executives · 29 May 2026
2,732,653 shares Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9597070-0 ● PDMR (Chief Financial Officer) · Executives · 29 May 2026
2,100,151 shares Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9597070-1 ● PDMR (Chief Executive Officer) · Executives · 29 May 2026
2,732,653 shares Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:5d364cb5-c38d-4e06-9a7d-bb54230bc2f5-0 ● PDMR (Chief Financial Officer) · Executives · 29 May 2026
2,100,151 shares Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:5d364cb5-c38d-4e06-9a7d-bb54230bc2f5-1 ● PDMR (Chief Financial Officer) · Executives · 13 May 2026
466 shares @ £32.3995 0.0035% mcap 100.0% of flow 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9568480-1 ● PDMR (Chief Executive Officer) · Executives · 13 May 2026
466 shares @ £32.3995 0.0035% mcap 100.0% of flow 1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:9568480-0 ● PDMR (Chief Financial Officer) · Executives · 13 May 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:46d290bf-32f1-4071-960e-9478ef06477f-1 ● PDMR (Chief Executive Officer) · Executives · 13 May 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:46d290bf-32f1-4071-960e-9478ef06477f-0 ● PDMR (Chief Executive Officer) · Executives · 15 Apr 2026
432,625 shares Outside a trading venueISIN ISIN GB00BL6NGV24RNS:77c79cb1-e087-4d88-bda7-6bcaf63ffd90-0 ● PDMR (Chief Executive Officer) · Executives · 15 Apr 2026
204,051 shares @ £0.6555 0.022% mcap 30.1% of flow XLONISIN ISIN GB00BL6NGV24RNS:77c79cb1-e087-4d88-bda7-6bcaf63ffd90-1 ● PDMR (Chief Executive Officer) · Executives · 14 Apr 2026
0
1. London Stock Exchange (XLON) 2. Outside of a trading venueISIN ISIN GB00BL6NGV24RNS:37e7bf27-02d0-4285-8e51-bd06f1f4f6fc-0 25 of 128 declarations
Load more (103 remaining) 关于 Dr. Martens plc Dr. Martens plc 是一家标志性的英国高端鞋履公司,在伦敦证券交易所(FTSE 100/250/AIM)上市,股票代码为 DOCS.L。该现代品牌于1960年4月1日在英格兰沃拉斯顿推出了第一款1460靴子,其商业起源可追溯至此。然而,它的根源可以追溯到克劳斯·马滕斯博士开发的战后气垫鞋底技术。随着时间的推移,该品牌从实用的工作靴演变为全球公认的自我表达、耐用性和青年文化的象征。公司总部位于伦敦,通过 EMEA、美洲和亚太三个区域中心运营,在欧洲、北美和亚太地区拥有广泛的商业足迹。
Dr. Martens 的商业模式围绕少数几个极具特色的产品系列构建。核心产品包括1460 8孔靴、1461 3孔鞋、2976切尔西靴,以及不断增长的鞋子、凉鞋、穆勒鞋、包袋和配饰系列。该品牌的视觉识别度极高:黄色沿条缝线、带凹槽的鞋底以及黑黄相间的后跟拉环使产品一目了然。这使得该集团在高端鞋履市场拥有持久的竞争地位,其竞争优势不在于销量,而在于品牌资产、文化相关性和产品一致性。它通过直接面向消费者和批发渠道服务客户,使其能够平衡覆盖范围、控制和商品销售灵活性。
从地理上看,英国仍然是该品牌的历史故乡,但 Dr. Martens 现在作为一个全球性消费品牌运营,并在主要市场进行本地化商业执行。其产品组合一直以标志性产品为核心,同时管理层继续推动向品牌 DNA 可信地延伸的相邻类别扩展。通过伦敦证券交易所的 RNS 发布的最新公开更新包括例行的董事/PDMR 股权通知、持股披露和交易更新,这些都突显了公司积极的市场沟通和遵守上市公司报告标准。最近的信息也强调了品牌主导的增长、运营纪律以及在业务稳定和领导层过渡后执行精炼战略。
对于投资者而言,Dr. Martens 提供了一个具有强大传统、全球知名度和多类别增长潜力的差异化高端鞋履特许经营权。与此同时,它仍然对可支配支出、时尚周期、渠道组合以及其国际零售和批发网络的执行质量的需求趋势敏感。